换一批
换一批Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
作者：
关键词
BOCCHCCMSCenters for Medicare and Medicaid ServicesCost-effectiveness analysisDAAF0, F1F2 or F4GTHCVHIVICERIFNIFN, BV, DAAInterferon-free oral treatmentMarkov modelNADACNational Average Drug Acquisition CostQALYsRBVSVRTVRTriple therapyWACboceprevirchronic hepatitis Cdirect, acting antiviral agentgenotypehepatitis Cimmunodeficiency virusincremental cost, effectiveness analysismild fibrosismoderate or advanced fibrosispegylated, interferon alphaquality, adjusted life years (a standard metric that incorporates both length and quality of life)ribavirinsustained virologic responsetelaprevirwholesale acquisition cost
主题词
抗病毒药(Antiviral Agents);费用效益分析(Cost-Benefit Analysis);药物疗法, 联合(Drug Therapy, Combination);基因型(Genotype);卫生保健费用(Health Care Costs);肝炎病毒属(Hepacivirus);丙型肝炎, 慢性(Hepatitis C, Chronic);人类(Humans);干扰素α(Interferon-alpha);聚乙烯二醇类(Polyethylene Glycols);重组蛋白质类(Recombinant Proteins);利巴韦林(Ribavirin)
DOI
10.1016/j.jhep.2013.11.009
PMID
24269472
发布时间
2022-04-09
- 浏览112
Journal of hepatology
530-7页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
